# MIROCALS: Modifying Immune Response and OutComes in ALS

> **NCT03039673** · PHASE2 · COMPLETED · sponsor: **Centre Hospitalier Universitaire de Nīmes** · enrollment: 304 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Riluzole
- **DRUG:** IL-2
- **DRUG:** 5% glucose water solution

## Key facts

- **NCT ID:** NCT03039673
- **Lead sponsor:** Centre Hospitalier Universitaire de Nīmes
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-19
- **Primary completion:** 2021-07-22
- **Final completion:** 2021-07-22
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03039673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03039673, "MIROCALS: Modifying Immune Response and OutComes in ALS". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03039673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*